{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pioglitazone+or+metformin", "query": { "intervention": "Pioglitazone or metformin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pioglitazone+or+metformin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T21:31:25.365Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00384215", "title": "Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin glargine [rDNA origin] injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 352, "start_date": "2001-12", "completion_date": "2005-02", "has_results": false, "last_update_posted_date": "2011-01-11", "last_synced_at": "2026-09-25T21:31:25.365Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00384215" }, { "nct_id": "NCT04416269", "title": "Oral Anti Diabetic Agents in the Hospital", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Oral Anti-diabetes Drugs alone", "type": "DRUG" }, { "name": "Basal bolus insulin", "type": "DRUG" }, { "name": "Supplemental insulin", "type": "DRUG" }, { "name": "Continuous glucose monitoring (CGM)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 85, "start_date": "2020-08-07", "completion_date": "2025-04-11", "has_results": true, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-25T21:31:25.365Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04416269" }, { "nct_id": "NCT00269061", "title": "Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Insulin-Dependent Diabetes Mellitus" ], "interventions": [ { "name": "pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 32, "start_date": "2006-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-10-16", "last_synced_at": "2026-09-25T21:31:25.365Z", "location_count": 1, "location_summary": "Belmont, Massachusetts", "locations": [ { "city": "Belmont", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00269061" }, { "nct_id": "NCT01798706", "title": "Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antidiabetic background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 350, "start_date": "2013-06", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-09-25T21:31:25.365Z", "location_count": 14, "location_summary": "La Jolla, California • Norwalk, California • Miami, Florida + 10 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Norwalk", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01798706" }, { "nct_id": "NCT00000620", "title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis", "Cardiovascular Diseases", "Hypercholesterolemia", "Hypertension", "Diabetes Mellitus, Type 2", "Diabetes Mellitus", "Coronary Disease" ], "interventions": [ { "name": "Anti-hyperglycemic Agents", "type": "DRUG" }, { "name": "Anti-hypertensive Agents", "type": "DRUG" }, { "name": "Blinded fenofibrate or placebo plus simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "40 Years to 79 Years" }, "enrollment_count": 10251, "start_date": "1999-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-09-25T21:31:25.365Z", "location_count": 6, "location_summary": "Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000620" }, { "nct_id": "NCT01289990", "title": "Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 10773", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sitagliptin 100mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2705, "start_date": "2011-02", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-07-15", "last_synced_at": "2026-09-25T21:31:25.365Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01289990" }, { "nct_id": "NCT00432276", "title": "Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Alogliptin", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 803, "start_date": "2007-01", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2013-04-04", "last_synced_at": "2026-09-25T21:31:25.365Z", "location_count": 86, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Lake Havasu City, Arizona + 83 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Lake Havasu City", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Foothill Ranch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00432276" }, { "nct_id": "NCT01064687", "title": "A Study in Participants With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "LY2189265", "type": "DRUG" }, { "name": "Exenatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 978, "start_date": "2010-02", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2015-01-26", "last_synced_at": "2026-09-25T21:31:25.365Z", "location_count": 78, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Cathedral City", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01064687" }, { "nct_id": "NCT01210001", "title": "Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "BI 10773", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 499, "start_date": "2010-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-17", "last_synced_at": "2026-09-25T21:31:25.365Z", "location_count": 24, "location_summary": "Muscle Shoals, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01210001" }, { "nct_id": "NCT00402909", "title": "Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Nateglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 28, "start_date": "2006-11", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2017-02-24", "last_synced_at": "2026-09-25T21:31:25.365Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402909" } ] }